Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaolin Sun

Showing results (331-340 of 335) with videos related to

Pageof 34
Sort By:
You have reached the last page of results.This site can display upto 335 results.
Nature Communications|April 21, 2026
Low dose IL-2 therapy restores regulatory T cells in patients with systemic lupus erythematosus in a dose-dependent manner: a phase IIb trialXia Zhang, Ruiling Feng, Yifan Wang, et al.
Immunity|October 22, 2013
Circulating precursor CCR7(lo)PD-1(hi) CXCR5⁺ CD4⁺ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposureJing He, Louis M Tsai, Yew Ann Leong, et al.
Nature Medicine|August 9, 2016
Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosusJing He, Xia Zhang, Yunbo Wei, et al.
Annals of the Rheumatic Diseases|April 3, 2019
Sequencing of the MHC region defines <i>HLA-DQA1</i> as the major genetic risk for seropositive rheumatoid arthritis in Han Chinese populationJianping Guo, Tao Zhang, Hongzhi Cao, et al.
JAMA Network Open|November 10, 2022
Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical TrialJing He, Jiali Chen, Miao Miao, et al.
Pageof 34

Showing results (331-340 of 335) with videos related to

Sort By:
Pageof 34
You have reached the last page of results.This site can display upto 335 results.
Nature Communications|April 21, 2026
Low dose IL-2 therapy restores regulatory T cells in patients with systemic lupus erythematosus in a dose-dependent manner: a phase IIb trialXia Zhang, Ruiling Feng, Yifan Wang, et al.
Immunity|October 22, 2013
Circulating precursor CCR7(lo)PD-1(hi) CXCR5⁺ CD4⁺ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposureJing He, Louis M Tsai, Yew Ann Leong, et al.
Nature Medicine|August 9, 2016
Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosusJing He, Xia Zhang, Yunbo Wei, et al.
Annals of the Rheumatic Diseases|April 3, 2019
Sequencing of the MHC region defines <i>HLA-DQA1</i> as the major genetic risk for seropositive rheumatoid arthritis in Han Chinese populationJianping Guo, Tao Zhang, Hongzhi Cao, et al.
JAMA Network Open|November 10, 2022
Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical TrialJing He, Jiali Chen, Miao Miao, et al.
Pageof 34